南方軸承(002553.SZ):泛亞微透科創板IPO順利過會
格隆匯 7 月 23日丨南方軸承(002553.SZ)公佈,公司於2020年7月22日在上海證券交易所網站獲悉,根據科創板上市委2020年第56次審議會議結果公告,公司參股公司江蘇泛亞微透科技股份有限公司(“泛亞微透”)提交的首次公開發行股票並在科創板上市的申請獲得審核通過。泛亞微透將會根據中國證監會及上海證券交易所的相關規定及要求開展後續工作。
至公告披露日,公司持有泛亞微透900萬股,佔其首次公開發行後總股本的12.86%。公司持有的泛亞微透上述股權自其上市之日起12個月內不得轉讓,敬請廣大投資者理性投資,注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.